Volume records cannot save a blockbuster franchise already priced for expiry.
When a single molecule carries three-quarters of revenue, federal price deals, formulary competition, and failed diversification trials compound into terminal-value collapse that record prescription volume cannot offset.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Record prescription volume still misses revenue estimates while the CagriSema diversification fails head-to-head — the exact pattern the law describes.
Even a 10x-patient volume ambition cannot reprice a franchise bracing for the 2032 semaglutide patent expiry, so the market values it as a turnaround rather than a growth leader.
Record Wegovy-pill prescription volume cannot offset net price erosion across a franchise priced for expiry.
Failed diversification trials compound the terminal-value collapse of a franchise whose core molecule carries the revenue.
Single-molecule concentration converts the 2030s loss-of-exclusivity cliff into a present-tense terminal-value downgrade, with even a $10B oral franchise 'not enough to offset pricing and competitive headwinds.'
Even record oral-launch volume cannot defend a franchise valuation already repriced for semaglutide expiry and lost market leadership.